Minimally invasive surgery (MIS) was previously considered an acceptable alternative to open radical hysterectomy in the management of early-stage cervical cancer (ESCC), but adequately powered, high-quality prospective trials evaluating survival outcomes were lacking. Recently, a large randomized phase III trial, the Laparoscopic Approach to Cervical Cancer (LACC) trial, showed that MIS for ESCC is associated with a higher risk of recurrence and death compared with open surgery. We review the LACC trial findings in depth, as well as a recent National Cancer Database analysis using propensity score weighting that supports the LACC trial findings. Additional studies are needed to better understand the mechanisms explaining the worse survival associated with MIS for ESCC. This review discusses considerations for integrating the findings of the LACC trial into clinical practice. Based on the high-quality evidence now available, open radical hysterectomy should be offered as standard of care for stage IA2–IB1 cervical cancer and patients should be guided appropriately to make informed shared decision-making if they still desire MIS.

Use of minimally invasive surgery (MIS) in the management of early-stage cervical cancer (ESCC), previously considered an acceptable alternative to open surgery,1 was recently challenged by results of the Laparoscopic Approach to Cervical Cancer (LACC) trial,2 which demonstrated inferior oncologic outcomes with minimally invasive radical hysterectomy compared with open radical hysterectomy. [Editors Note: The “Principles of Evaluation and Surgical Staging” and accompanying discussion in the NCCN Guidelines for Cervical Cancer, Version 3.2019, published in this issue and on NCCN.org, have been updated to highlight the oncologic risks associated with minimally invasive approaches for radical hysterectomy.] In prior retrospective studies, laparoscopic radical hysterectomy was associated with less blood loss, shorter hospital stay, and fewer complications compared with open radical hysterectomy,3–6 but did not seem to have higher recurrence or worse survival rates.6–12 However, most of these studies were retrospective single-institution studies lacking adequate power to compare oncologic outcomes. In addition, randomized clinical trials in other cancer types (early-stage endometrial cancer, colorectal cancer) showed similar survival with a minimally invasive approach compared with open surgery.13–16

The LACC trial was an international, multicenter, randomized phase III trial of women with stage IA1 (with lymphovascular space invasion), IA2, or IB1 cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix who were randomized to undergo either open radical hysterectomy (laparotomy) or laparoscopic/robotic radical hysterectomy (type II or III Piver-Rutledge classification). The trial was designed to test for noninferiority of minimally invasive radical hysterectomy (total laparoscopic or robotic radical hysterectomy) compared with open radical hysterectomy, with a planned sample size of 740 patients and 4.5 years of follow-up, to show that MIS was within 7.2% of the disease-free survival (DFS) rate of the open surgery arm, with at least 90% power for noninferiority (based on a 97.5% one-sided CI). Inclusion characteristics of both groups were similar, and there were no significant differ-
ences in postoperative histopathologic differences between groups with respect to histology, grade, tumor size (<2 vs ≥2 cm), lymphovascular space invasion, parametrial involvement, or lymph node involvement, although grade and depth of invasion were not reported in approximately 30% of cases. The MIS group had a higher rate of superficially invasive tumors (28.5% vs 21.6% in the open surgery group). Other pathologic findings were similar: 12% of women in the MIS group versus 13% of those in the open group had positive lymph nodes, and parametrial involvement was present in 7% and 4% of individuals in each group, respectively. Similar rates of postoperative adjuvant therapy were administered in both groups (29% in MIS group, 28% in open group).

The study was terminated prematurely after 85% of the planned accrual (n=631) based on recommendations by the Data Safety and Monitoring Committee due to higher rates of recurrence and death in the MIS arm. DFS at 4.5 years was 86.0% in the MIS group and 96.5% in the open surgery group (between-group difference, −10.6 percentage points; 95% CI, −16.4 to −4.7; P=.87 for noninferiority) based on intention-to-treat analysis. Per-protocol analysis revealed similar findings. Minimally invasive radical hysterectomy was associated with a significantly lower DFS than open surgery, with a hazard ratio (HR) for disease recurrence or death from cervical cancer of 3.74 (95% CI, 1.63–8.58), which persisted after adjustment for age, body mass index (BMI), cancer stage, lymphovascular space invasion, lymph node involvement, and performance status. Overall survival (OS) was also significantly worse in the MIS group (3-year OS, 93.8% vs 99% for open surgery; HR for death from any cause, 6.00; 95% CI, 1.77–20.3), as was cancer-specific survival (3-year rate of death from cervical cancer, 4.4% vs 0.6% for open surgery; HR, 6.56; 95% CI, 1.48–29.0). Women in the MIS arm had a significantly higher rate of locoregional recurrence (3-year rate of locoregional recurrence-free survival, 94.3% vs 98.3% for MIS; HR for locoregional recurrence, 4.26; 95% CI, 1.44–12.60).

The unexpected negative results of the LACC trial are staggering: women who received MIS for ESCC were almost 4 times more likely to experience recurrence and were 6.6 times more likely to die of their cancer than those who underwent open surgery. Importantly, although median length of hospital stay was shorter for MIS compared with open surgery (3 vs 5 days), no significant differences were seen in the rates of intraoperative complications, serious adverse events, or long-term morbidities between arms.2 Quality of life was assessed using the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), Short Form-12 (SF-12), M.D. Anderson Symptom Inventory (MDASI), and EuroQol-5D (EQ-5D), and reassuringly, almost all general and disease-specific health-related quality of life scores were similar between groups at all timepoints.17 Mobility was decreased in the open surgery group compared with the MIS group at postoperative week 1, but these differences resolved by 6 weeks postoperatively.

Some limitations of the trial included missing data in some patients, a lack of standardization of adjuvant treatment, no central pathology review, and lack of data on patient race and ethnicity. Nonetheless, reported overall inclusion characteristics, postoperative histopathologic findings, and rates of adjuvant treatment were similar between groups.

Findings from a recent population-based study by Melamed et al18 using the National Cancer Database (NCDB) were also consistent with the LACC trial findings of worse oncologic outcomes with MIS. The NCDB analysis included 2,461 patients at Commission on Cancer–accredited US hospitals diagnosed with stage IA2 or IB1 cervical cancer (squamous cell, adenosquamous, or adenocarcinoma) between 2010 and 2013 and treated with radical hysterectomy as primary treatment (49.8% minimally invasive). Using extremely robust statistical methods with inverse probability of treatment propensity-score weighting, they found that women treated with MIS had decreased 4-year OS compared with those treated with open surgery (90.9% vs 94.7%; P=.002), with an HR for death of 1.65 (95% CI, 1.22–2.22). Although unmeasured confounding or patient selection is always a concern in any nonrandomized study, women in the MIS group would have actually been predicted to have longer survival compared with those in the open surgery group due to their younger age, higher socioeconomic status, and lower tumor grade.

The same authors also performed an interrupted time-series analysis of women who underwent radical hysterectomy for cervical cancer during 2000 to 2010 in the SEER database, and found that the adoption of MIS coincided with an 0.8% decline in 4-year relative survival rate per year after 2006 (95% CI, 0.3–1.4; P=.01 for change of trend). A recent subset analysis of the same NCDB population focusing on patients with tumors ≥2 cm also documented a decreased 5-year OS rate for the MIS versus open surgery approach (HR, 2.14; 95% CI, 1.36–3.38; P<.001).19 Why did the recent population-based study by Melamed et al19 demonstrate inferior oncologic outcomes with MIS, when prior retrospective studies reported similar outcomes compared with open surgery? Prior studies were limited by low power, shorter follow-up, and likely confounding. For example, even in a relatively large matched cohort study by Nam et al7 of 526 women with stage IA2 to IIA cervical cancer who underwent radical hysterectomy (open vs MIS) with a median follow-up of 91 months, those in the MIS group were not found to have a statistically higher risk of death compared with those in the open surgery group. However, the HR for
An additional consideration is whether the

1.50; 95% CI, 0.97–2.31) (Figure 1). Thus, we feel it would

laparoscopic radical hysterectomy were each associated

analyses found that both robotic-assisted and traditional

CO2 pneumoperitoneum may increase wound and peritoneal metastases compared with laparotomy or gasless laparoscopy,[20–22] although other studies have failed to demonstrate a difference.[23,24] An additional consideration is whether the extent of resection differs between minimally invasive and open surgical approaches for radical hysterectomy. One single-institution study suggested that robotic surgery was associated with a higher rate of close surgical margins compared with open surgery, although only 20 cases were robotic and may have been performed during the robotic surgery learning curve. In addition, close surgical margins were not an independent predictor of recurrence in this analysis.[25]

In the LACC trial, no differences were seen between arms in the rates of positive vaginal margins (2% in each arm); rates of close surgical margins were not reported.

With the published findings of the LACC trial available, we have an obligation to our patients to practice evidence-based medicine and determine how to appropriately integrate the findings into our clinical practice. Concerns have been raised regarding whether these results should be applied to robotic surgery (vs traditional laparoscopy). Proponents of robotic surgery may argue that the inferior outcomes observed with MIS in the LACC trial cannot be generalized to robotic surgery specifically because of the 289 participants in the MIS arm, only 45 (16%) had robotic surgery. However, a per-protocol sensitivity analysis of DFS at 4 years revealed nearly identical differences between 4-year DFS rates in the laparoscopy and robotic arms compared with the open arm (laparoscopic: −10.6% absolute difference in DFS [95% CI, −16.4 to −4.7]; robotic: −10.4% absolute difference DFS [95% CI, −24.7 to 3.9]). In the study by Melamed et al,[18] nearly 80% of patients in the MIS cohort underwent robotic radical hysterectomy, and exploratory subgroup analyses found that both robotic-assisted and traditional laparoscopic radical hysterectomy were each associated with a higher risk of death compared with open surgery (robotic: HR, 1.61; 95% CI, 1.18–2.21; laparoscopic: HR, 1.50; 95% CI, 0.97–2.31) (Figure 1). Thus, we feel it would be inappropriate to reassure patients that robotic surgery has similar outcomes compared with open surgery based on the data available.

Even surgeons with extensive experience using MIS to treat ESCC should not be tempted to conclude that the results of the LACC trials are not applicable to them. The LACC trial involved high-volume, experienced cervical cancer surgeons. To ensure proper surgical technique during MIS in the LACC trial, surgeons at participating sites were required to provide 2 unedited videos of a total laparoscopic or robotic radical hysterectomy procedure, independently reviewed by 2 members of the Trial Management Committee, as well as perioperative outcomes of 10 cases. In addition, no sites or individual surgeons performed only the MIS or only the open approach for cervical cancer management.

Importantly, surgeons should not inform patients that they have reviewed their own personal data, and that, in their specific hands, patients can expect equivalent outcomes regardless of surgical approach. As Ramirez et al discussed, retrospective studies (whether largescale or surgeon-specific) are often sequential rather than concurrent analyses, in which patients in the open surgery group likely were treated during an earlier time frame, when indications for radical hysterectomy were broader (including patients with stage IB2 disease), recommendations for radiotherapy may not have been clearly defined, or the addition of chemotherapy was not standard practice. In addition, smaller concurrent analyses are likely subject to confounding factors, including significant selection bias. Single-surgeon and even single-institutional analyses would be significantly underpowered to detect the difference between patients having MIS or open surgery.

Whether MIS should be offered to patients with lower-risk ESCC (tumors <2 cm) is uncertain. Neither the LACC trial nor the Melamed et al[18] study were adequately powered to evaluate oncologic outcomes in patients with tumors <2 cm. In the LACC trial, 52% of patients in each trial arm had tumors <2 cm: 147 in the open surgery group and 150 in the MIS group; 6 recurrences occurred in patients with tumors <2 cm. Disease recurrence occurred in 1 patient (0.68%) in the open surgery group and 5 (3.33%) in the MIS group. Although the number of recurrences in each group was small, a post hoc subgroup analysis could not distinguish a different impact by surgical approach for smaller versus larger tumors. The NCDB analysis by Melamed et al[18] found that the association between MIS and increased all-cause mortality remained across histologic type and tumor sizes (Figure 1). Specifically, for tumor size <2 cm, the HR for death was 1.46 (95% CI, 0.70–3.02), and although the CI crossed 1, the association was consistent with that seen in the primary analysis and in all subanalyses. The authors comment that they were unable
to precisely estimate the association between MIS and mortality in the subgroup of women who had tumors <2 cm because there were few deaths in that subgroup. Based on the available data, we have concerns about offering MIS even to women with tumors <2 cm, and recommend that women be counseled that it is unknown whether MIS can offer similar oncologic outcomes to open surgery for these smaller lesions.

Although the LACC trial did not find any differences in rates of intraoperative complications, serious adverse events, or long-term mortalities between arms, the potential increased morbidity of open surgery compared with MIS remains relevant. Median BMI of participants in the LACC trial was only 26 kg/m^2 (range, 21–32 kg/m^2), which is likely significantly lower than the average BMI for patients with ESCC in the United States. In a recent analysis by Uppal et al\[^{26}\] of 7,180 patients treated with radical hysterectomy for cervical cancer in the National Inpatient Sample from 2012 through 2015 in the United States, 10% had a BMI of 30.0 to 39.9, and an additional 5% had a BMI ≥40. In this study, the overall rate of at least one complication during hospitalization after open surgery was 24.8% compared with 10% in MIS cases (P<.001), with a higher risk of infectious and medical complications, but not surgical complications, associated with open surgery. Nonetheless, the potential increased risk of complications likely does not supersede the concern regarding a 6-fold higher risk of dying associated with MIS for unselected patients. For the much smaller subset of patients who are at significantly high risk of major complications or severe morbidity with open surgery, perhaps primary chemoradiation (which has equivalent oncologic outcomes to open surgery) should be a consideration.

In summary, MIS for ESCC is associated with a higher risk of recurrence and death compared with open surgery. The level I evidence presented by the randomized controlled LACC trial should not be ignored in favor of earlier level II–III data from smaller, retrospective studies when guiding clinical decision-making. Additional studies are needed to better understand the mechanisms explaining these contemporary findings and to determine whether any subgroups of patients could still routinely benefit from MIS, even if they have smaller tumors. It is critical to counsel patients accordingly. Based on the high-level evidence from the LACC trial and the NCDB analysis, open radical hysterectomy should be offered as standard of care for stage IA2–IB1 cervical cancer and patients should be guided appropriately to make informed shared decision-making if they still desire MIS.

Submitted December 9, 2018; accepted for publication December 17, 2018.

Disclosures: The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Kathryn P. Pennington, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 NE Pacific Street, Box 356460, Seattle, WA 98195-6460. Email: katypenn@u.washington.edu

---

**Figure 1.** Subgroup analyses by showing the associations between minimally invasive radical hysterectomy and all-cause mortality according to mode of MIS, histologic type, and tumor size.

Abbreviations: HR, hazard ratio; MIS, minimally invasive surgery.


<table>
<thead>
<tr>
<th>Subgroup</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical approach</td>
<td></td>
</tr>
<tr>
<td>Laparoscopic</td>
<td>1.50 (0.97–2.31)</td>
</tr>
<tr>
<td>Robotic</td>
<td>1.61 (1.18–2.21)</td>
</tr>
<tr>
<td>Histologic type</td>
<td></td>
</tr>
<tr>
<td>Squamous cell</td>
<td>1.65 (1.17–2.33)</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>2.22 (1.08–4.55)</td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
</tr>
<tr>
<td>&lt;2 cm</td>
<td>1.46 (0.70–3.02)</td>
</tr>
<tr>
<td>≥2 cm</td>
<td>1.66 (1.19–2.30)</td>
</tr>
</tbody>
</table>

![Diagram](image-url)
References


